Cargando…
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313937/ https://www.ncbi.nlm.nih.gov/pubmed/30241300 http://dx.doi.org/10.3390/vaccines6040066 |
_version_ | 1783384046436352000 |
---|---|
author | Kim, Ki-Hye Kwon, Young-Man Lee, Young-Tae Kim, Min-Chul Hwang, Hye Suk Ko, Eun-Ju Lee, Youri Choi, Hyo-Jick Kang, Sang-Moo |
author_facet | Kim, Ki-Hye Kwon, Young-Man Lee, Young-Tae Kim, Min-Chul Hwang, Hye Suk Ko, Eun-Ju Lee, Youri Choi, Hyo-Jick Kang, Sang-Moo |
author_sort | Kim, Ki-Hye |
collection | PubMed |
description | Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines induce innate and protective adaptive immune responses. Despite the high antigenic properties of 5xM2e proteins, the 5xM2e VLP was superior to 5xM2e proteins in inducing IgG2a isotype antibodies, T cell responses, plasma cells and germinal center B cells as well as in conferring cross protection. Mice primed with 5xM2e VLP were found to be highly responsive to 5xM2e protein boost, overcoming the low immunogenicity and protective efficacy of 5xM2e proteins. Immunogenic differences between VLPs and proteins in priming immune responses might be due to an intrinsic ability of 5xM2e VLP to stimulate dendritic cells secreting T helper type 1 (Th1) cytokines. We also found that 5xM2e VLP was effective in inducing inflammatory cytokines and chemokines, and in recruiting macrophages, monocytes, neutrophils, and CD11b(+) dendritic cells at the injection site. Therefore, this study provides evidence that 5xM2e VLP is an effective vaccine platform, inducing cross-protection by stimulating innate and adaptive immune responses. |
format | Online Article Text |
id | pubmed-6313937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63139372019-01-07 Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus Kim, Ki-Hye Kwon, Young-Man Lee, Young-Tae Kim, Min-Chul Hwang, Hye Suk Ko, Eun-Ju Lee, Youri Choi, Hyo-Jick Kang, Sang-Moo Vaccines (Basel) Article Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines induce innate and protective adaptive immune responses. Despite the high antigenic properties of 5xM2e proteins, the 5xM2e VLP was superior to 5xM2e proteins in inducing IgG2a isotype antibodies, T cell responses, plasma cells and germinal center B cells as well as in conferring cross protection. Mice primed with 5xM2e VLP were found to be highly responsive to 5xM2e protein boost, overcoming the low immunogenicity and protective efficacy of 5xM2e proteins. Immunogenic differences between VLPs and proteins in priming immune responses might be due to an intrinsic ability of 5xM2e VLP to stimulate dendritic cells secreting T helper type 1 (Th1) cytokines. We also found that 5xM2e VLP was effective in inducing inflammatory cytokines and chemokines, and in recruiting macrophages, monocytes, neutrophils, and CD11b(+) dendritic cells at the injection site. Therefore, this study provides evidence that 5xM2e VLP is an effective vaccine platform, inducing cross-protection by stimulating innate and adaptive immune responses. MDPI 2018-09-20 /pmc/articles/PMC6313937/ /pubmed/30241300 http://dx.doi.org/10.3390/vaccines6040066 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Ki-Hye Kwon, Young-Man Lee, Young-Tae Kim, Min-Chul Hwang, Hye Suk Ko, Eun-Ju Lee, Youri Choi, Hyo-Jick Kang, Sang-Moo Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title_full | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title_fullStr | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title_full_unstemmed | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title_short | Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus |
title_sort | virus-like particles are a superior platform for presenting m2e epitopes to prime humoral and cellular immunity against influenza virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313937/ https://www.ncbi.nlm.nih.gov/pubmed/30241300 http://dx.doi.org/10.3390/vaccines6040066 |
work_keys_str_mv | AT kimkihye viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT kwonyoungman viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT leeyoungtae viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT kimminchul viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT hwanghyesuk viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT koeunju viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT leeyouri viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT choihyojick viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus AT kangsangmoo viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus |